Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO in a ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning ...